Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3320118 | 0.99 | KDM4E (0.70) | KDM4ETSHRMAPTKMT2ADRD3 | |
| SCHEMBL3049241 | 0.92 | DRD3 (0.71) | KDM4ETSHRMAPTDRD3TDP1 | |
| SCHEMBL3059563 | 0.89 | REV1 (0.66) | KDM4ETSHRMAPTKMT2ADRD3 | |
| SCHEMBL6132005 | 0.88 | KDM4E (0.59) | KDM4ETSHRMAPTKMT2ADRD3 | |
| SCHEMBL3058767 | 0.87 | KDM4E (0.55) | KDM4ETSHRMAPTKMT2ADRD3 | |
| SCHEMBL3041492 | 0.87 | CA9 (0.69) | KDM4ETSHRMAPTKMT2ADRD3 | |
| SCHEMBL3324219 | 0.82 | KDM4E (0.63) | KDM4ETSHRMAPTKMT2ADRD3 | |
| SCHEMBL10421792 | 0.82 | POLB (0.62) | KDM4ETSHRMAPTKMT2ADRD3 | |
| SCHEMBL4762852 | 0.82 | PDE4B (0.79) | KDM4ETSHRMAPTKMT2APOLB | |
| SCHEMBL10753092 | 0.82 | POLB (0.62) | KDM4ETSHRMAPTKMT2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185521-A2 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | Exonhit Therapeutics SA (FR) | 2010-05-19 | — | — | EP | disclosed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | disclosed |
| WO-2009007457-A2 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007457-A2 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2009-01-15 | — | — | WO | disclosed |
| EP-2014651-A1 | Compounds and methods for modulating Rho GTPases | Exonhit Therapeutics SA (FR) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | RAC1, RAC2, RAC3 | KDM4E 3958/4885TSHR 4376/4885MAPT 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.